World's Best Scientists 2026 revealed!
Gregor Verhoef

Gregor Verhoef

D-Index & Metrics

Medicine

D-Index
91
Citations
41324
World Ranking
11572
National Ranking
139

Gregor Verhoef publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gregor Verhoef sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 538 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gregor Verhoef D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gregor Verhoef sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gregor Verhoef is affiliated with KU Leuven in Belgium and has contributed extensively to the field of Medicine, with a particular focus on oncology-related disciplines. Their research encompasses diverse subfields, including Pathology and Forensic Medicine, Genetics, Oncology, Neurology, and Hematology.

Verhoef's work often centers on lymphoma and leukemia research, addressing both diagnosis and treatment approaches. The main topics of their research include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • CNS Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Viral-associated cancers and disorders
  • Glioma Diagnosis and Treatment

The scientist regularly publishes in several key medical journals that focus on hematology and oncology, notably:

  • Blood
  • Leukemia & lymphoma/Leukemia and lymphoma
  • Leukemia
  • Cancer Immunology Immunotherapy
  • Journal of Clinical Oncology

Gregor Verhoef has collaborated frequently with other researchers in related fields. Notable co-authors include:

  • Daan Dierickx
  • Thomas Tousseyn
  • Peter Vandenberghe
  • Lukas Marcelis
  • Koen Debackere

Among their recent papers are important clinical and therapeutic studies, including:

  • "Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)," published in the Journal of Clinical Oncology in 2020
  • "Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma," published by Leukemia & lymphoma/Leukemia and lymphoma in 2020
  • "Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier," published in Blood in 2020
  • "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma," published in Leukemia in 2020
  • "In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy," published in Cancer Immunology Immunotherapy in 2020

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Stromal gene signatures in large-B-cell lymphomas

    G Lenz;G Wright;S S Dave;W Xiao

  • High-dose daunorubicin in older patients with acute myeloid leukemia.

    Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten

  • Acquired mutations in TET2 are common in myelodysplastic syndromes

    Saskia M C Langemeijer;Roland P Kuiper;Marieke Berends;Ruth Knops

  • Galactomannan and Computed Tomography–Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study

    Johan Maertens;Koen Theunissen;Gregor Verhoef;Johnny Verschakelen

  • Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients

    P Wijermans;M Lübbert;Gregor Verhoef;A Bosly

  • ALK+ Lymphoma: Clinico-Pathological Findings and Outcome

    Brunangelo Falini;Stefano Pileri;Pier Luigi Zinzani;Antonino Carbone

  • Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    Georg Hess;Raoul Herbrecht;Jorge Romaguera;Gregor Verhoef

  • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

    Lucien Noens;Marie Anne Van Lierde;Robrecht De Bock;Gregor Verhoef

  • Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

    Dimitri A. Breems;Wim L.J. Van Putten;Peter C. Huijgens;Gert J. Ossenkoppele

  • Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

    Johan Maertens;Jan Verhaegen;Hilde Demuynck;Penelope Brock

  • Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

    K. Spaepen;S. Stroobants;P. Dupont;P. Vandenberghe

  • Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18f]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma : Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

    Karoline Spaepen;Sigrid Stroobants;Patrick Dupont;Steven Van Steenweghen

  • Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia

    Koenraad Devriendt;Annette S. Kim;Gert Mathijs;Suzanna G M Frints

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

    Tadeusz Robak;Huiqiang Huang;Jie Jin;Jun Zhu

  • High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani;Claudia Erpelinck;Wim L. J. van Putten;Peter J. M. Valk

  • An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

    Gregor Verhoef;Hans E Johnsen;Francesca Gaia Rossi;Antonio Salar

Frequent Co-Authors

Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Bob Löwenberg
Bob Löwenberg Erasmus MC
Stefania Pittaluga
Stefania Pittaluga National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens a range of opportunities beyond the traditional MD route. Online education has made it more accessible than ever to pursue diverse health-related roles. For those interested in pharmacy, pharmd online programs provide a flexible path to become a Doctor of Pharmacy, combining clinical expertise with patient care skills.

The demand for tech-savvy professionals is rising in healthcare. Pursuing a degree in health informatics prepares graduates to manage patient data, improve systems, and ensure data security. Similarly, a medical coding certification opens doors to careers in billing, coding, and healthcare administration—vital roles that keep clinics and hospitals running smoothly.

For those with a passion for patient care, there are also most affordable nurse practitioner programs available online, offering advanced clinical training and leadership development. These varied pathways enable students to join the healthcare sector in ways that best fit their interests and lifestyles.

Best Scientists Citing Gregor Verhoef

Trending Scientists

Recently Published Articles